1. Home
  2. TBBK vs SUPN Comparison

TBBK vs SUPN Comparison

Compare TBBK & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Bancorp Inc

TBBK

The Bancorp Inc

N/A

Current Price

$46.91

Market Cap

2.1B

Sector

Finance

ML Signal

N/A

Logo Supernus Pharmaceuticals Inc.

SUPN

Supernus Pharmaceuticals Inc.

N/A

Current Price

$42.44

Market Cap

2.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TBBK
SUPN
Founded
1999
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.5B
IPO Year
2005
2010

Fundamental Metrics

Financial Performance
Metric
TBBK
SUPN
Price
$46.91
$42.44
Analyst Decision
Buy
Buy
Analyst Count
3
4
Target Price
★ $76.00
$60.50
AVG Volume (30 Days)
414.4K
★ 912.1K
Earning Date
10-29-2026
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 14.69
N/A
EPS
★ 2.86
N/A
Revenue
$141,147,000.00
★ $392,755,000.00
Revenue This Year
N/A
$21.56
Revenue Next Year
$0.56
$55.45
P/E Ratio
$17.69
★ N/A
Revenue Growth
★ 20.85
N/A
52 Week Low
$47.01
$37.54
52 Week High
$73.02
$59.68

Technical Indicators

Market Signals
Indicator
TBBK
SUPN
Relative Strength Index (RSI) 33.14 53.06
Support Level N/A $41.86
Resistance Level $51.47 $51.59
Average True Range (ATR) 1.47 2.13
MACD 0.26 0.23
Stochastic Oscillator 9.70 70.75

Price Performance

Historical Comparison
TBBK
SUPN

About TBBK The Bancorp Inc

The Bancorp Inc is a financial holding company. The Company's operations are classified under three segments: fintech, Credit Solutions (three sub-segments), and corporate. The fintech segment includes the deposit balances and non-interest income generated by prepaid, debit, and other card-accessed accounts, ACH processing, and other payments-related processing. It also includes loan balances and interest and non-interest income from credit products generated through payment relationships; Credit Solutions includes REBL (real estate bridge lending), comprised of apartment building rehabilitation loans, and Others; Corporate includes the Company's investment securities, corporate overhead, and expenses which have not been allocated to segments.

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

Share on Social Networks: